STSA 1301
Alternative Names: STSA-1301Latest Information Update: 19 Aug 2024
At a glance
- Originator Staidson Beijing BioPharmaceuticals
- Class Monoclonal antibodies; Recombinant proteins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Thrombocytopenia
Most Recent Events
- 03 Apr 2024 Staidson completes a phase I trial in Thrombocytopenia (In volunteers) in China (SC) (NCT06148389)
- 29 Nov 2023 Phase-I clinical trials in Thrombocytopenia (In volunteers) in China (SC) (NCT06148389)
- 31 Oct 2023 Staidson (Beijing) Biopharmaceuticals receives approval for a clinical trial application from State Drug Administration in China for Thrombocytopenia